Bundibugyo Ebolavirus Vaccine
Prevention of Bundibugyo ebolavirus infection
ResearchNIH-funded development
Key Facts
Indication
Prevention of Bundibugyo ebolavirus infection
Phase
Research
Status
NIH-funded development
Company
About Auro Vaccines
Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.
View full company profile